The system can lock its payload in place and control how it is released
A new injectable material designed to deliver drug therapies and sensor technology to targeted areas within the human body is being developed by a Texas A&M University biomedical engineer who says the system can lock its payload in place and control how it is released.
The research, led by Michael McShane, professor in the Department of Biomedical Engineering who specializes in biomaterials, and graduate student Jason Roberts, appears in “Journal of Materials Chemistry B.” It details the development of a carrier system embedded with microscopic capsules that act as tiny reservoirs for medicines or even sensors that would alert a person in critical instances, such as when blood-sugar levels change.
The technology, McShane notes, affords researchers a high degree of control over what is delivered to the body, where and when it is delivered and how much of it is delivered. That degree of flexibility, he says, could make the system an extremely useful tool when it comes to targeted drug delivery.
As opposed to having patients simply swallow a pill, health care professionals have long envisioned delivering specific quantities of medicines to targeted areas of the body, thereby increasing the treatment’s effectiveness while reducing side effects. In order to achieve this, a “vehicle” of sorts is needed to safely and accurately deliver the medicine to the desired location within the body.
McShane’s team, which also includes graduate student Dustin Ritter, is building that vehicle using a modified Jell-O-like substance known as a hydrogel. A hydrogel is a polymer mesh material that is typically biocompatible, meaning it allows cells within the body to conduct normal physiological processes without triggering an immune response from the host. Because of this, hydrogels are widely used in tissue engineering research, and they can be found in a number of other applications, most commonly as the material from which contact lenses are made.
Although hydrogels aren’t new, the ones employed in McShane’s carrier system aren’t typical; they’ve been enhanced. Specifically, they are embedded with tiny capsules that are significantly smaller than the width of a human hair. Each of these microcapsules serves as a reservoir or depot for the material doctors and researchers want to deliver, such as a drug.
Measuring a few microns in diameter, these porous microparticles are made from clusters of calcium carbonate nanoparticles that have been deliberately formed around a specific material to trap it inside, McShane notes. Once the desired material is trapped within the microsphere, multiple layers of polymers are wrapped around the particles, he explains. This allows for a precise and customizable control over how the microcapsule will release its contents when it interacts with its surrounding environment, McShane explains.
The system, McShane says, is not limited to drug delivery. In fact, it has shown promising results with biosensors. In these types of applications, he explains, the microcapsules carry a payload, such as a protein, that is responsive to something in the body that doctors want to measure. This measurable material is allowed to pass into the hydrogel and into the capsules where it triggers some type of optical change, he says. For example, McShane has been able to trigger a color change in the material (observable with a reader device) when pH and oxygen levels change or when blood-sugar levels fluctuate. It’s work that could translate into safer and more effective ways for people, such as those suffering from diabetes, to monitor their conditions.
The Latest on: Targeted drug delivery
No news articles
via Google News
The Latest on: Targeted drug delivery
- LabCorp Introduces Xcellerate® COVID-19 Clinical Study Solutionon June 29, 2020 at 4:37 am
LabCorp (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced that Covance, its drug d ...
- All Eyes on BioNTech's COVID-19 Vaccineon June 29, 2020 at 4:04 am
We think the market has assigned a premium to the shares because of the potential upside of the company’s COVID-19 vaccine program, so the valuation does not look compelling at this point. However, ...
- Advanced & Targeted Drug Delivery Market begins to take bite out of Versioned Long Term Growthon June 25, 2020 at 7:32 am
Latest Study on Industrial Growth of Global Advanced & Targeted Drug Delivery Market 2019-2025. A detailed study accumulated to offer Latest insights about acute features of the Advanced & Targeted ...
- Protein and RNA Used to Create Vesicles for Potential Drug Deliveryon June 24, 2020 at 1:00 pm
Scientists from the University at Buffalo and Iowa State University use protein, RNA to make hollow, spherical sacks called vesicles that could potentially be engineered to deliver drugs.
- FMI Analyzes Impact of COVID-19 on Connected Drug Delivery Devices Market ; Stakeholders to Focus on Long-term Dimensionson June 24, 2020 at 12:10 pm
Global Healthcare Sector Outlook in Light of the Global Connected Drug Delivery Devices MarketDespite the economic and political uncertainty in the recent past, the global healthcare industry has been ...
- The Europe pharmaceutical drug delivery market is anticipated to reach US$ 5,62,102.6 Mn by 2027 from US$ 3,52,775.1 Mn in 2019on June 19, 2020 at 5:42 pm
The market is projected to grow at a CAGR of 6. The pharmaceutical drug delivery market is growing primarily due to the increase in the number of naturally occurring outbreaks. The increasing cases of ...
- Controlled Release Drug Delivery Market Share and Growth Factors Impact Analysis 2020 - 2027on June 19, 2020 at 11:13 am
The global controlled release drug delivery market size was valued at USD 37.8 billion in 2019 and is anticipated ...
- Test maker targeted by FDA says it responded to US concernson June 18, 2020 at 6:53 am
A company targeted by the Food and Drug Administration for selling unauthorized coronavirus antibody tests says it has responded to regulators' concerns, though it has no business ...
- Macrophage mimetics to target atherosclerosison June 11, 2020 at 4:30 am
A new biomimetic drug delivery system consisting of nanoparticles that are coated with macrophage membrane and responsive to reactive oxygen species (ROS) enables targeted pharmacotherapy for ...
- Combo therapy, nanoparticle delivery system show promise for pancreatic canceron June 8, 2020 at 8:02 am
A new multi-drug combination therapy for pancreatic cancer is inching toward clinical trials in humans. The drug compound, called SapC-DOPS, combines chemotherapy with targeted therapy and can kill ...
via Bing News